Sec. 3002. PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE
486 words·~2 min read·
/statute-compilations/comps-13005/sec-3002A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 3002 PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE ###
(a)Publication of Guidance Documents Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Commissioner of Food and Drugs, shall develop a plan to issue draft and final versions of one or more guidance documents, over a period of 5 years, regarding the collection of patient experience data, and the use of such data and related information in drug development. Not later than 18 months after the date of enactment of this Act, the Secretary shall issue a draft version of at least one such guidance document. Not later than 18 months after the public comment period on the draft guidance ends, the Secretary shall issue a revised draft guidance or final guidance. ###
(b)Patient Experience Data For purposes of this section, the term “patient experience data” has the meaning given such term in section 569C of the Federal Food, Drug, and Cosmetic Act (as added by section 3001). ###
(c)Contents The guidance documents described in subsection
(a)shall address— ####
(1)methodological approaches that a person seeking to collect patient experience data for submission to, and proposed use by, the Secretary in regulatory decisionmaking may use, that are relevant and objective and ensure that such data are accurate and representative of the intended population, including methods to collect meaningful patient input throughout the drug development process and methodological considerations for data collection, reporting, management, and analysis; ####
(2)methodological approaches that may be used to develop and identify what is most important to patients with respect to burden of disease, burden of treatment, and the benefits and risks in the management of the patient’s disease; ####
(3)approaches to identifying and developing methods to measure impacts to patients that will help facilitate collection of patient experience data in clinical trials; ####
(4)methodologies, standards, and technologies to collect and analyze clinical outcome assessments for purposes of regulatory decisionmaking; ####
(5)how a person seeking to develop and submit proposed draft guidance relating to patient experience data for consideration by the Secretary may submit such proposed draft guidance to the Secretary; ####
(6)the format and content required for submissions under this section to the Secretary, including with respect to the information described in paragraph (1); ####
(7)how the Secretary intends to respond to submissions of information described in paragraph (1), if applicable, including any timeframe for response when such submission is not part of a regulatory application or other submission that has an associated timeframe for response; and ####
(8)how the Secretary, if appropriate, anticipates using relevant patient experience data and related information, including with respect to the structured risk-benefit assessment framework described in section 505(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(d)), to inform regulatory decisionmaking.
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 3002
PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE
Cites 1Cited by 0 across 0 sources